Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Yue Fei, Man-Fung Tsoi, Cyrus R. Kumana, et al.
International Journal of Cardiology (2017) Vol. 254, pp. 291-296
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 129
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
Sharen Lee, Jiandong Zhou, Keith Sai Kit Leung, et al.
Cardiovascular Drugs and Therapy (2022) Vol. 37, Iss. 3, pp. 561-569
Open Access | Times Cited: 42
Advances in rehabilitation for chronic diseases: improving health outcomes and function
Caroline R. Richardson, Barry A. Franklin, Marilyn L. Moy, et al.
BMJ (2019), pp. l2191-l2191
Closed Access | Times Cited: 71
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 10, pp. 904-917
Closed Access | Times Cited: 5
Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials
Edoardo Mannucci, Ilaria Dicembrini, Besmir Nreu, et al.
Diabetes Obesity and Metabolism (2019) Vol. 22, Iss. 2, pp. 203-211
Closed Access | Times Cited: 42
Heat-not-burn tobacco products and cardiovascular risk reduction: A systematic review of randomized controlled trials
Edin Begić, Buena Aziri, Elma Omeragić, et al.
Technology and Health Care (2023) Vol. 31, Iss. 4, pp. 1457-1491
Closed Access | Times Cited: 12
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Xiaodong Zhuang, Xin He, Daya Yang, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 36
Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services
Chi‐Hsien Huang, Hiroyuki Umegaki, Yuuki Watanabe, et al.
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0211947-e0211947
Open Access | Times Cited: 34
Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
Bhavani Shankara Bagepally, Yogesh K. Gurav, Thunyarat Anothaisintawee, et al.
Value in Health (2019) Vol. 22, Iss. 12, pp. 1458-1469
Open Access | Times Cited: 34
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Gurav, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 1, pp. e001020-e001020
Open Access | Times Cited: 29
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
Osamah M. Alfayez, Majed S. Al Yami, Mohannad Alshibani, et al.
Primary care diabetes (2019) Vol. 13, Iss. 3, pp. 204-211
Closed Access | Times Cited: 25
The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Ya Luo, Kai Lü, Gang Liu, et al.
Clinical Drug Investigation (2018) Vol. 38, Iss. 12, pp. 1089-1108
Closed Access | Times Cited: 15
<p>Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials</p>
Deborah Hinnen, Davida F. Kruger
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 447-455
Open Access | Times Cited: 15
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
G. Grenet, Shams Ribault, Giao Bao Nguyen, et al.
PLoS ONE (2019) Vol. 14, Iss. 6, pp. e0217701-e0217701
Open Access | Times Cited: 15
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheung
Cardiac failure review (2021) Vol. 7
Open Access | Times Cited: 12
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
Juan Ling, Long Ge, Zhang Ding-hua, et al.
Acta Diabetologica (2018) Vol. 56, Iss. 1, pp. 7-27
Closed Access | Times Cited: 12
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Michael Heile, Kathleen Wyne, Liana K. Billings, et al.
Journal of Managed Care & Specialty Pharmacy (2018) Vol. 24, Iss. 9-a Suppl, pp. S42-S52
Open Access | Times Cited: 10
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2
Srikanth Yandrapalli, Aaqib H. Malik, Adam Horblitt, et al.
Cardiology in Review (2020) Vol. 28, Iss. 5, pp. 219-235
Closed Access | Times Cited: 9
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus—Part 1
Srikanth Yandrapalli, George Jolly, Adam Horblitt, et al.
Cardiology in Review (2020) Vol. 28, Iss. 4, pp. 177-189
Closed Access | Times Cited: 7
Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan
Eric P. Borrelli, Peter Saad, Nathan E Barnes, et al.
Journal of Managed Care & Specialty Pharmacy (2024), pp. 1-13
Closed Access
Highlights from the International Journal of Cardiology Heart & Vasculature: Heart failure, atrial fibrillation, coronary artery disease and myocardial infarction
Dominik Linz, Enrico Ammirati, Gheorghe‐Andrei Dan, et al.
IJC Heart & Vasculature (2019) Vol. 25, pp. 100443-100443
Open Access | Times Cited: 3
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
Elizabeth Wehler, Dominik Lautsch, Stacey Kowal, et al.
PharmacoEconomics (2020) Vol. 39, Iss. 3, pp. 317-330
Open Access | Times Cited: 3
Non-alcoholic fatty liver disease and risk of cardiovascular diseases: clinical association, pathophysiological mechanisms, and management
Rong Yang, Jian‐Gao Fan
Cardiology Plus (2023) Vol. 8, Iss. 4, pp. 217-226
Open Access | Times Cited: 1
Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
Awadhesh Kumar Singh, Viral N. Shah
Clinical Diabetology (2022) Vol. 11, Iss. 4, pp. 215-221
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top